Khiron Life Sciences Corp. announces its new medical product portfolio in Europe. The new products, which are already being promoted to prescribers, pharmacies, and patients, will be exclusively distributed through Khiron's wholly-owned Pharmadrug Production GmbH and will be available to pharmacies and patients in Germany and the UK in the coming weeks.

The THC-dominant full-spectrum extract KHIRIOX 25/1 combines the medicinal properties and areas of application of the established THC isolate formulations (dronabinol) with the specific advantages of a full spectrum extract. This new product is based on Khiron's current top selling and effective extract formulation in Latin America. Khiron will also introduce non-irradiated flower varieties KHIRON Gelato 19/1 and KHIRON Caramel 5/7. These varieties are very popular in California among consumers and patients and are in very high demand in Europe.